In COVID-19 clinical update #86, Dr. Griffin discusses virologic features of infection in children, antibody tests should not be used to asses level of protection, test-to-stay programs in schools, FDA authorizes Moderna boosters, results of TOGETHER trial for fluvoxamine, statins and 28 day mortality, and cognitive function in patients.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• 115,000 healthcare worker deaths (Stat News)
• Virology features of infection in children (J Inf Dis)
• Antibody tests not for assessing protection (FDA)
• Infections in vaccinated healthcare workers (NEJM)
• Flawed science of antibody testing (JAMA)
• Test-to-stay in school (US News)
• Vaccination and non-COVID mortality risk (MMWR)
• EUA for Moderna booster (FDA)
• Fact sheet for use of casirivimab and imdevimab (FDA)
• Effect of early treatment with fluvoxamine (Lancet)
• Statins and 28-day mortality (J Inf Dis)
• Cognitive function after COVID-19 (JAMA)
• Routine vaccination coverage worldwide (MMWR)
• Letters read on TWiV 823
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]